Patent SG-11201803692P-A (SG)
Title: Anti-5t4 antibodies and antibody-drug conjugates
Inventor: VAN DER LEE MIRANDA MARIA CORNELIA
IPC: C07K16/30
Filed: 2016-11-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1 June 2017 (01.06.2017) WIPOIPCT (10) International Publication Number WO 2017/089447 A1 (51) International Patent Classification: A61K39/44 (2006.01) C07K16/30 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/EP2016/078642 (22) International Filing Date: (25) Filing Language: (26) Publication Language 24 November 2016 (24.11.2016) English English (30) Priority Data: 15195978.0 24 November 2015 (24.11.2015) 16191272.0 29 September 2016 (29.09.2016) EP EP (71) Applicant: SYNTHON BIOPHARMACEUTICALS B.V. [NL/NL]; Microweg 22, 6545CM Nijmegen (NL). (72) Inventors: VAN DER LEE, Miranda Maria Cornelia; Synthon Biopharmaceuticals B.V., Microweg 22, 6545 CM Nijmegen (NL). ARIAANS, Gerardus Joseph Andreas; Synthon Biopharmaceuticals B.V., Microweg 22, 6545 CM Nijmegen (NL). SCHOUTEN, Jan; Synthon Biopharma­ ceuticals B.V., Microweg 22, 6545 CM Nijmegen (NL). BLOMENROHR, Marion; Synthon Biopharmaceuticals B.V., Microweg 22, 6545 CM Nijmegen (NL). GROOTHUIS, Patrick Gerhard; Synthon Biopharma­ ceuticals B.V., Microweg 22, 6545 CM Nijmegen (NL). COUMANS, Rudy Gerardus Elisabeth; Synthon Bio­ pharmaceuticals B.V., Microweg 22, 6545 CM Nijmegen (NL). (74) Agent: YISSCHER, Inge; P.O. Box 7071, 6503 GN Nijmegen (NL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) < Tf Tf ON 00 (54) Title: ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES <N (57) : The present disclosure relates to CDR defined antibodies targeting the 5T4 oncofoetal antigen (TPBG, 5T4, Wnt Ac­ tivated Inhibitory Factor 1, WAIF 1) which exhibit a binding affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4. Antibody-drug conjugates (ADCs), and their use in the treatment of human solid tu­ mours and haematological malignancies are claimed. O